

Special Issue

Identification of Novel Compounds against Multidrug-Resistant Cancer Cells

Message from the Guest Editors

Multidrug resistance (MDR) is among the major reasons for chemotherapy failure and cancer progression. In addition to ATP-binding cassette (ABC) transporters, various additional mechanisms are involved in which the tumour cells arrange themselves and continue to proliferate even in the presence of chemotherapy drugs. Inhibitors of ABC transporters can increase the efficiency of chemotherapy to some extent, but because of the multifactorial nature of MDR phenomena, novel inhibitors to target different MDR mechanisms are required. For this purpose, various MDR-associated proteins are awaiting targeting with natural compounds or synthetic derivatives to identify novel inhibitors to overcome MDR phenomena and increase chemotherapy success rates. This special issue of *Pharmaceuticals* on the “Identification of Novel Compounds against Multidrug-Resistant Cancer Cells” will include both regular articles and reviews focused on the most recent advances in the identification of novel compounds against multidrug-resistant cancer cells.

Guest Editors

Dr. Onat Kadioglu

Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany

Prof. Dr. Thomas Efferth

Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany

Deadline for manuscript submissions

closed (20 October 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/55728

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)